hVIVO - an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge.
hVIVO is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in influenza (flu), respiratory syncytial virus (RSV), human rhinovirus (HRV) and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health.
Leading the way in these areas, hVIVO is now experiencing significant interest in expanding the concept into product development for airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cough, where cost, time and risks associated with achieving clinical proof of concept are considerable. These opportunities provide valuable and exciting opportunities to expand our services and increase our revenues.
Our vision is to become a partner of choice for companies developing products in airways disease
Deliver fast proof of concept outcomes that can lead to more efficient drug development programmes. Executing and delivering our clients’ clinical development needs.